CO-VANTAGE-DATA-CENTERS
13.12.2022 14:01:34 CET | Business Wire | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, announced today the construction of a second campus (JNB2) in Johannesburg, South Africa.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213005272/en/
JNB11 facility on Vantage Data Centers' developing 80MW campus in Johannesburg, South Africa. The company is now developing a second campus 17 kilometers away. (Photo: Business Wire)
The JNB2 Isando campus is strategically located in Ekurhuleni, the greater Johannesburg Metropol’s trade and industry hub, and approximately 17 kilometers from Vantage’s growing JNB1 Midrand campus. JNB2 is sited near the OR Tambo International Airport and less than two kilometers from the NAPAfrica neutral Internet eXchange in a region that serves as the cloud on-ramp for a number of large technology companies.
“South Africa continues to be a cornerstone for Vantage’s EMEA growth outside of continental Europe,” said Antoine Boniface, president, Vantage Data Centers, EMEA. “Investing in a second campus is a testament to our commitment to the region and our customers who have business requirements to be in this high-demand market.”
The first building of the JNB2 campus will consist of a 20MW 355,000 square foot (33,000 square meters) two-story data center and will be operational in mid-2024. Vantage is repurposing a portion of an existing warehouse for the initial phase, reducing the embodied carbon of the development.
Sustainable Design
Many features of JNB2 are based on Vantage’s standardized campus blueprint, emphasizing sustainable construction practices. This includes offering renewable energy options through a recent Power Purchase Agreement with SolarAfrica, limiting carbon footprints, maintaining energy efficient operations with an industry-leading power usage effectiveness (PUE) and minimizing the use of water.
Power and Cooling
The first data center on the JNB2 campus will be cooled using a highly efficient, closed-loop chilled water system generated through air-cooled chillers. An integrated economizer capability will allow reduced compressor energy based on outside ambient temperature. This allows Vantage to take advantage of cooler seasonal temperatures to minimize resource usage. Customers will benefit from power provided by the Municipality of Ekurhuleni, combined with a dedicated on-site, high-voltage substation.
Security and Amenities
Campus security remains a priority for Vantage, and the company’s hallmark security measures include an on-site security operations center with 24x7x365 patrols, perimeter security, CCTV on all access points, and multi-level authentication and access controls for employees, customers and visitors.
This new data center will provide dedicated offices and workspaces, break areas, conference rooms, meeting spaces and secure storage areas.
JNB1 Expansion
On Vantage’s inaugural and award-winning 80MW campus in Midrand, South Africa, the company opened its first 16MW facility in July 2022, and continues expanding the development to meet customer demand. The next phase is under construction and is slated to be operational in early 2024.
For more information about Vantage’s global campus footprint, visit https://vantage-dc.com/data-center-locations/.
About Vantage Data Centers
Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.
For more information, visit www.vantage-dc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005272/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom